Eicosapentaenoic acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Eicosapentaenoic acid Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Eicosapentaenoic acid can convert its Small molecule drug profile and Lipid x PPARγ biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Eicosapentaenoic acid (query alias: Eicosapentaenoic acid) |
|---|---|
| Modality / target | Small molecule drug; Lipid x PPARγ; Lipid modulators, PPARγ agonists |
| Highest global status | Phase 3 |
| Originator | 1 A Pharma GmbH |
| Active developers | S.L.A. Pharma AG, 1 A Pharma GmbH |
The MCP disease footprint includes Post Acute COVID 19 Syndrome, COVID-19. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600123747 | Not Applicable | Not yet recruiting | 1300 | Incidence of Acute Kidney Injury (AKI) within 7 days postoperatively |
| JPRN-UMIN000061490 | Not Applicable | 参加者募集終了‐試験継続中/No longer recruiting | 800 | サプリメントの糖尿病に対する効果に関する信念。4種類のサプリメント（ローヤルゼリー、DHAとEPA、大豆イソフラボン、カルシウム）について、血糖値の調整、血糖値を調整するインスリンの働きの改善、および糖尿病予防に対する有効性の信念を各3項目、計12項目で評価する。各項目は1「まったくそう思わない」から6「非常にそう思う」までの6件法で測定する。評価は介入メッセージまたは対照メッセージの閲覧前および閲覧直後に実施する。主要解析では、閲覧後スコアを主要評価指標とする。 |
| ChiCTR2600126705 | Not Applicable | Not yet recruiting | 60 | Muscle mass |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGFβ inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (CSCC)
Phase 1; n=14; evaluation: Positive. Reported fields: ORR = 42 % ( 15.2 - 72.3)
A Randomized, Comparative Study of HEMAX PFS® Versus EPREX/ ERYPO® in the Treatment of Anemia With Epoetin Alfa in Patients With Predialysis Chronic Kidney Disease
Phase 3; n=43; evaluation: not stated. Reported fields: Baseline hemoglobin levels(Mean) = 9.44 Hemoglobin levels (g/dL) (Standard Deviation, 0.81); Baseline hemoglobin levels(Mean) = 9.56 Hemoglobin levels (g/dL) (Standard Deviation, 0.60); -
Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients
Not Applicable; n=73; evaluation: not stated. Reported fields: Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo(Median) = 1.3 cm H2O (Inter-Quartile Range, 0 - 1.7); -; Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo(Median) = 0.1 cm H2O (Inter-Quartile Range, -1.4 to 3.2)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Eicosapentaenoic acid addresses Post Acute COVID 19 Syndrome, COVID-19. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Lipid x PPARγ records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| No matched asset transaction returned. | |||
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Use of PPAR full agonist in combination with THR-β agonist in resisting of metabolic-related diseases”. The milestone feed surfaced a patent-application signal described as “Enzyme based production of specialized pro-resolving mediators (SPMS) via docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)”. The milestone feed surfaced a patent-application signal described as “Method for increasing yield of eicosapentaenoic acid in schizochytrium sp.”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
